• 文献检索
  • 文档翻译
  • 深度研究
  • 学术资讯
  • Suppr Zotero 插件Zotero 插件
  • 邀请有礼
  • 套餐&价格
  • 历史记录
应用&插件
Suppr Zotero 插件Zotero 插件浏览器插件Mac 客户端Windows 客户端微信小程序
定价
高级版会员购买积分包购买API积分包
服务
文献检索文档翻译深度研究API 文档MCP 服务
关于我们
关于 Suppr公司介绍联系我们用户协议隐私条款
关注我们

Suppr 超能文献

核心技术专利:CN118964589B侵权必究
粤ICP备2023148730 号-1Suppr @ 2026

文献检索

告别复杂PubMed语法,用中文像聊天一样搜索,搜遍4000万医学文献。AI智能推荐,让科研检索更轻松。

立即免费搜索

文件翻译

保留排版,准确专业,支持PDF/Word/PPT等文件格式,支持 12+语言互译。

免费翻译文档

深度研究

AI帮你快速写综述,25分钟生成高质量综述,智能提取关键信息,辅助科研写作。

立即免费体验

PMID:25855840
Abstract

BACKGROUND

Bone morphogenetic proteins (BMP) are key factors necessary for bone regeneration and healing. Recombinant DNA techniques have been used to produce BMP2 and BMP7 as alternatives to autograft bone to enhance healing of bony defects and fractures in patients where autograft bone harvest is unfeasible or contraindicated. Currently, two rhBMPs and four associated carrier/delivery systems (one of which has been voluntarily withdrawn from the U.S. market) have received approval as devices from the U.S. Food and Drug Administration (FDA). The InFUSE® system (Medtronic Sofamor Danek, Inc.) consists of rhBMP2 on an absorbable collagen sponge carrier. OP-1® (Stryker Biotech) consists of rhBMP7 and bovine collagen, which is reconstituted with saline to form a paste. The addition of carboxymethylcellulose forms putty.

METHODS

This assessment is based on an electronic search of the literature as follows: MEDLINE® (January 1, 1998, through July 28, 2009). EMBASE® (January 1, 1998, through July 28, 2009). Cochrane Controlled Trials Register (no date restriction). The searches were updated in February 2010. The interventions of interest for all Key Questions (see table, following) are the use of either of the two commercially available BMP products in the U.S. Interventions were considered to be delivered on-label when administered according to the indication specified in the FDA-approved marketing label. All other uses and applications of BMP products were considered off-label. Studies were selected to address 10 Key Questions identified for this technology assessment. In general, we abstracted data from full-length randomized, controlled trials (RCTs) and nonrandomized, comparative trials that utilized BMP therapy in patients with a bony defect that required intervention and reported at least one outcome of interest. The quality of included studies was assessed using the general approach to grading evidence developed by the U.S. Preventive Services Task Force (USPSTF). The strength of the overall body of evidence was assessed using a framework developed by AHRQ for the EPC Methods Guide, based on a system developed by the GRADE Working Group.

RESULTS

The electronic literature search yielded 1,992 records. Among those, 1,738 were excluded at initial title and abstract review and 254 were retrieved for full text examination. Forty-one articles describing results of comparative studies were abstracted.

摘要

相似文献

1
2
3
Folic acid supplementation and malaria susceptibility and severity among people taking antifolate antimalarial drugs in endemic areas.在流行地区,服用抗叶酸抗疟药物的人群中,叶酸补充剂与疟疾易感性和严重程度的关系。
Cochrane Database Syst Rev. 2022 Feb 1;2(2022):CD014217. doi: 10.1002/14651858.CD014217.
4
Osteogenic protein-1 for long bone nonunion: an evidence-based analysis.用于治疗长骨骨不连的成骨蛋白-1:一项循证分析
Ont Health Technol Assess Ser. 2005;5(6):1-57. Epub 2005 Apr 1.
5
BMP 2--Genetics Institute/ Medtronic-Sofamor Danek/Integra. Bone morphogenetic protein 2--Genetics Institute/ Medtronic-Sofamor Danek/Integra, INFUSE Bone Graft, recombinant human bone morphogenetic protein 2--Genetics Institute/Medtronic-Sofamor Danek/Integra, RhBMP 2--Genetics Institute/Medtronic-Sofamor Danek/Integra.骨形态发生蛋白2——基因研究所/美敦力-索法莫·丹尼克/英特格拉公司。骨形态发生蛋白2——基因研究所/美敦力-索法莫·丹尼克/英特格拉公司,INFUSE骨移植产品,重组人骨形态发生蛋白2——基因研究所/美敦力-索法莫·丹尼克/英特格拉公司,重组人骨形态发生蛋白2——基因研究所/美敦力-索法莫·丹尼克/英特格拉公司。
BioDrugs. 2002;16(5):376-7. doi: 10.2165/00063030-200216050-00007.
6
Balloon kyphoplasty: an evidence-based analysis.球囊椎体后凸成形术:一项基于证据的分析。
Ont Health Technol Assess Ser. 2004;4(12):1-45. Epub 2004 Dec 1.
7
8
9
10
Airway clearance devices for cystic fibrosis: an evidence-based analysis.用于囊性纤维化的气道清理装置:一项基于证据的分析。
Ont Health Technol Assess Ser. 2009;9(26):1-50. Epub 2009 Nov 1.